- In July 2026, Avantor announced that its NuSil brand is expanding its collaboration with the Population Council to support development of a new three-month dapivirine vaginal ring for HIV prevention, building on its prior work supplying ultra-high-purity silicones for the already-approved one-month ring used across sub-Saharan Africa.
- This next-generation, longer-duration ring could meaningfully improve adherence, reduce annual costs, and broaden access to HIV prevention for women in high-prevalence regions, underscoring NuSil’s role in specialized medical-grade silicone solutions.
- We’ll now examine how NuSil’s expanded role in a three-month HIV prevention ring could influence Avantor’s broader investment narrative.
The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Avantor Investment Narrative Recap
To own Avantor, you need to believe its mix of lab consumables, bioprocessing and high-value niches like medical silicones can support a durable, profitable platform even as growth has been patchy and recent results unprofitable. The NuSil HIV-prevention ring collaboration highlights the specialty-medtech side of the story, but it does not change the fact that the key near term catalyst remains any sustained improvement in bioprocessing demand, while the biggest risk is continued margin pressure tied to pricing and weak volumes.
Among recent announcements, the Q1 2026 results are most relevant, with revenue roughly flat at US$1,581.4 million and limited earnings support for the investment case. Against that backdrop, NuSil’s role in higher value medical-grade silicone applications, such as the three month dapivirine ring now under regulatory review, may be interesting for investors watching whether Avantor can gradually tilt its portfolio toward technically differentiated products that are less exposed to pricing pressure in its core lab solutions business.
Yet alongside the NuSil opportunity, you still need to weigh the risk that persistent pricing pressure and weak demand could keep margins under strain for longer than many investors expect...
Read the full narrative on Avantor (it's free!)
Avantor's narrative projects $6.9 billion revenue and $566.4 million earnings by 2029.
Uncover how Avantor's forecasts yield a $10.31 fair value, a 6% downside to its current price.
Exploring Other Perspectives
While the NuSil news hints at upside, the most pessimistic analysts were still assuming only about 1.3% annual revenue growth and roughly US$425.0 million in earnings by 2029, reminding you that views on Avantor’s long term potential can differ widely and are worth comparing side by side.
Explore 2 other fair value estimates on Avantor - why the stock might be worth 6% less than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Avantor research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Avantor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Avantor's overall financial health at a glance.
Curious About Other Options?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
- Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com